目的 統(tǒng)計2020—2022年安徽省胸科醫(yī)院抗結(jié)核藥物使用情況并分析其變化趨勢，為規(guī)范其合理應用提供一定參考。方法 對2020年1月—2022年12月安徽省胸科醫(yī)院抗結(jié)核藥物銷售金額、用藥頻度（DDDs）、日均費用（DDC）以及金額排序/DDDs排序比（B/A）等進行統(tǒng)計分析。結(jié)果 2020—2022醫(yī)院抗結(jié)核藥物銷售金額總體呈增長趨勢，新型類抗結(jié)核藥物銷售金額2022年較2020年增幅333.43%，注射類降幅72.68%，貝達喹啉、注射用利奈唑胺、環(huán)絲氨酸、氯法齊明排名靠前，其中貝達喹啉連續(xù)2年銷售金額排名第1位。DDDs每年總體基本穩(wěn)定，排名靠前的為一線口服類抗結(jié)核藥物：異煙肼、乙胺丁醇、吡嗪酰胺、利福平，2022年DDDs貝達喹啉排名第1位。利奈唑胺等40.00%抗結(jié)核藥物DDC降低。每年一線口服類抗結(jié)核藥物B/A均大于1，2022年B/A＞0.9的藥物占比達60.00%。結(jié)論 安徽省胸科醫(yī)院抗結(jié)核藥物使用基本合理，仍然需要加強監(jiān)督管理，減小耐藥結(jié)核發(fā)生率。

Objective To investigate anti-tuberculosis drugs usage in Anhui Chest Hospital from 2020 to 2022 and analyze its change trend, so as to provide reference for regulating its rational application. Methods Annual consumption sums, DDDs, DDC, and the B/A of anti-tuberculosis drugs in Anhui Chest Hospital from January 2020 to December 2022 were analyzed statistically. Results From 2020 to 2022, consumption sums of anti-tuberculosis drugs in the hospital showed an overall increasing trend, and consumption sums of new anti-tuberculosis drugs increased by 333.43% in 2022 compared with 2020, while consumption sums of injection drugs decreased by 72.68%. Bedaquiline, linezolid for injection, cycloserine, and clofazimine ranked top, among which bedaquiline ranked first for two consecutive years. DDDs were basically stable every year, and the top ones were first-line oral anti-tuberculosis drugs, such as isoniazid, ethambutol, pyrazinamide, and rifampicin. In 2022, bedaquiline ranked first. DDC of 40.00% anti-tuberculosis drugs such as linezolid decreased. The B/A of first-line oral anti-tuberculosis drugs was greater than 1. In 2022, drugs with B/A＞0.9 accounted for 60.00%. Conclusion The use of anti-tuberculosis drugs in Anhui Chest Hospital was basically reasonable, and supervision and management should be strengthened to reduce the incidence of anti-tuberculosis drugs.

R978.3